NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease

What Is This Study About?

This Phase II study will evaluate the efficacy of the experimental drug T-817MA as a possible treatment for people with mild to moderate Alzheimer's disease. Its impact on cognition and daily functioning will be measured by standard tests.

Do I Qualify To Participate in This Study?

Must have:

• Diagnosis of mild to moderate Alzheimer's disease
• Taking the medication donepezil (Aricept) or rivastigmine transdermal system (Exelon patch); memantine (Namenda) is allowed only when prescribed in combination with donepezil or the rivastigmine transdermal system
• Living in the community
• Study partner or caregiver who has regular contact with participant (at least 10 hours per week) and can accompany his/her to study visits
• Participant and caregiver able to read and understand English
• Female participants must be postmenopausal or surgically sterile

Must NOT have:

• Clinically significant cardiac, hepatic, or renal impairment
• Non-Alzheimer's dementia (for example, vascular dementia, frontotemporal disorder, Lewy body dementia)
• Taking any drug for Alzheimer's disease other than donepezil or the rivastigmine transdermal system, including oral rivastigmine (Exelon) or galantamine (Razadyne)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Who Sponsors This Study?

Lead: Toyama Chemical Co., Ltd.

Collaborator Sponsor

• Alzheimer's Disease Cooperative Study (ADCS)

Source: ClinicalTrials.gov ID: NCT02079909